These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 11055685)

  • 1. Antiarrhythmic agents and proarrhythmia.
    Chaudhry GM; Haffajee CI
    Crit Care Med; 2000 Oct; 28(10 Suppl):N158-64. PubMed ID: 11055685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J
    Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic agents: drug interactions of clinical significance.
    Trujillo TC; Nolan PE
    Drug Saf; 2000 Dec; 23(6):509-32. PubMed ID: 11144659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symposium on the management of ventricular dysrhythmias. Antifibrillatory versus antiectopic therapy.
    Anderson JL
    Am J Cardiol; 1984 Jul; 54(2):7A-13A. PubMed ID: 6147079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification of antiarrhythmic agents: electropharmacologic basis and clinical relevance.
    Coromilas J
    Cardiovasc Clin; 1992; 22(1):97-116. PubMed ID: 1309443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring: antiarrhythmic drugs.
    Campbell TJ; Williams KM
    Br J Clin Pharmacol; 1998 Oct; 46(4):307-19. PubMed ID: 9803978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of amiodarone in contemporary management of complex cardiac arrhythmias.
    Mujović N; Dobrev D; Marinković M; Russo V; Potpara TS
    Pharmacol Res; 2020 Jan; 151():104521. PubMed ID: 31756386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs and the heart. IV. Antiarrhythmic agents.
    Opie LH
    Lancet; 1980 Apr; 1(8173):861-8. PubMed ID: 6103220
    [No Abstract]   [Full Text] [Related]  

  • 17. Overview of the clinical pharmacology of antiarrhythmic drugs.
    Woosley RL; Funck-Brentano C
    Am J Cardiol; 1988 Jan; 61(2):61A-69A. PubMed ID: 2447771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions.
    Nattel S; Singh BN
    Am J Cardiol; 1999 Nov; 84(9A):11R-19R. PubMed ID: 10568655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The pro-arrhythmic effects of anti-arrhythmia agents].
    Haverkamp W; Wichter T; Chen X; Hördt M; Willems S; Rotman B; Hindricks G; Kottkamp H; Borggrefe M; Breithardt G
    Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of class I and III antiarrhythmic drugs on ventricular tachycardia-interrupting critical paced cycle length with rapid pacing.
    Naitoh N; Washizuka T; Takahashi K; Aizawa Y
    Jpn Circ J; 1998 Apr; 62(4):267-73. PubMed ID: 9583460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.